INTRODUCTION {#s1}
============

Mouse embryonic stem cells (mESCs) are the *in vitro* counterparts of an *in vivo* population of cells specific to the early embryo within the inner cell mass. ES cells are pluripotent and different culture conditions can induce them to differentiate into the three primary germ layers (mesoderm, ectoderm and endoderm). In the mouse embryo around 6.5 days of gestation, epiblast cells migrate to form the primitive streak which contains the nascent mesoderm. Derived from mesoderm, hematopoiesis occurs in a consequent temporal pattern during embryonic development, around 7.5 days gestation in the blood islands in the yolk sac. Associated with this process is the formation of the hemangioblast population. This transient progenitor cell with the capacity to give rise to both endothelial and hematopoietic progenitors has been shown to be formed within the primitive streak \[[@R1]\].

mESCs have been studied extensively since they represent a potentially vast source of cells and tissues for regenerative medicine. Although there are data on the molecular processes governing the formation of hemangioblasts \[[@R2]\], specific phosphorylation events within the nucleus governing development have not yet been systematically analysed, and the mechanistic detail on how the hemangioblast is formed requires further analysis.

To further delineate the hemangioblast population, a reporter ES cell line with the GFP coding sequences targeted into the Brachyury (Bry) locus was created by Fehling et al \[[@R3]\]. ES cells can differentiate *in vitro* to form spheroid cultures called embryonic bodies (EBs). These structures contain the derivatives of all the three germ layers, and it is possible to track mesoderm and hematopoietic lineage commitment *in vitro* with the temporal expression of two specific genes, restricted to the lineage of interest. Bry, a member of the T-box gene family, is a marker for the early mesoderm formation (the majority of the cells in the primitive streak are Bry positive). Bry expression decreases when cells migrate away from the primitive streak and further differentiate. Flk1, the vascular endothelial growth factor receptor 2, identifies a mesodermal population of cells further committed for differentiation and is commonly expressed with Bry in populations with hematopoietic potential. The analysis of Bry and Flk1 expression allowed for the detection of three subpopulations: the Bry^−^Flk1^−^ population represents mES cells that have not yet undergone the differentiation process, thus resembling epiblast cells. The Bry^+^Flk1^−^ fraction corresponds to a population of early mesoderm differentiating cells. The Bry^+^Flk1^+^ fraction contains precursors for endothelial and hematopoietic lineages, the blast-colony forming cells (BL-CFC), representing the *in vitro* equivalent of the hemangioblast.

We have previously reported changes occurring in mES cells nuclear proteome during mesoderm-induced differentiation, using isobaric tags for relative and absolute quantification (iTRAQ^TM^) coupled to LC-MS/MS analysis \[[@R4]\]. This approach allowed a relatively deep proteomic penetration. However, activities of proteins are often regulated by translation and degradation rates, as well as by post-translational modifications, e.g. phosphorylation. It has been recently reported that post-translational modifications occur during ES cells differentiation, and they are also required for ES cell self-renewal \[[@R5]\]. Protein phosphorylation has been demonstrated to be involved in the regulation of many aspects of cellular functions including cell proliferation, differentiation, migration and signal transduction. It is likely that extracellular signals in part convey their signals to the nucleus to engender epigenetic changes to initiate altered gene transcription \[[@R6]\]. In the process of mesoderm formation some signaling molecules have defined roles in proliferation and development control, such as tumor growth factor beta, FGF, Wnt and Hedgehog families; in mouse, BMP4, Wnt3 or Nodal, are essential for mesoderm development \[[@R7]--[@R8]\]. Mice lacking canonical Wnt ligands do not develop the primitive streak and fail to generate mesoderm from the epiblast \[[@R9]--[@R11]\]. Therefore the Wnt signaling pathway is involved in the mechanism that induces mouse ES cells to differentiate, switching from self-renewal to differentiation. Phosphorylation mapping, by means of proteomic technologies, serves as a starting point for establishing a comprehensive database of the stem cell phosphoproteome. To define the phosphoproteome of hemangioblast cells, we compared it with that of epiblast-like and early mesoderm populations. Our observations provide potential new pathways for analysis of regulation in ES cell differentiation to the hemangioblast fate, that could also be unraveled in leukemias. Interestingly, recent findings propose a pivotal role for GSK3 and the chromatin remodeling factor Smarcc1/Baf155 in the decision fate of hematopoietic stem cells to differentiate. GSK3 is an important regulator of stem cell homeostasis, in particular ES cell self-renewal \[[@R12]\], but it also been recently implicated in leukemia stem cell physiology \[[@R13]--[@R14]\]. Smarcc1/Baf155 is necessary for heterochromatin formation and chromatin compaction during the differentiation process.

RESULTS {#s2}
=======

Phosphoproteomic analysis of early embryonic development {#s2_1}
--------------------------------------------------------

Once cultured without LIF and embryonic feeders, ES cells differentiate *in vitro* toward the mesoderm lineage. Three different populations, Bry^−^Flk1^−^, Bry^+^Flk1^−^ and Bry^+^Flk1^+^, were isolated from the differentiating ES cell culture as previously described \[[@R3]\] (Figure [1A](#F1){ref-type="fig"}). These distinct populations have been seen to represent epiblast, mesoderm committed and blast like colony forming (BL-CFC) cells. Approximately 1 × 10^7^ cells were collected for each population, nuclear enrichment was performed to concentrate the downstream proteomic analysis on pathways associated with regulation of gene expression ([Figure S1](#SD1){ref-type="supplementary-material"}). The same amount of each nuclear protein tryptic lysates (100 μg) was labeled with one of the 4-plex iTRAQ^TM^ channel reagents. All four reagents were used, allowing one internal control within the same LC-MS/MS experiment (Bry^−^Flk1^−^ nuclear lysate was labeled with two different iTRAQ^TM^ reagents) (Figure [1B](#F1){ref-type="fig"}). The samples were combined and enrichment for phosphopeptides performed using the TiO~2~ metal affinity enrichment approach. Samples were fractionated using SCX chromatography, before LC-MS/MS analysis. Data recorded from two independent biological replicates were analyzed using the Paragon Algorithm within the ProteinPilot^TM^ v.3.0. The total number of phosphopeptides identified was 2506, present in the two biological replicates, with 20% of confidence ([Table S1](#SD2){ref-type="supplementary-material"}). The data acquired showed a normal distribution between biological replicates with a modal value centered around 0 (1 in the linear scale) (Figure [1C](#F1){ref-type="fig"}).

![(A) Flow cytometric sorting of ES cells at specific time points of the hematopoietic differentiation for nuclear phosphoproteome analysis\
Differentiating ES cells were enriched based on Bry and Flk1 expression. 2 × 10^7^ cells were used for each experiment. At 2.5 days of differentiation, Bry^−^Flk1^−^ cells, corresponding to the epiblast-like stage, were collected by flow cytometric sorting (1). At 3.5 days two other populations, Bry^+^Flk1^−^ and Bry^+^Flk1^+^, corresponding to the mesoderm and hemangioblast (BL-CFC) cell populations, respectively, were collected (2). **(B)** Schematic workflow for the identification of changes in the phosphoproteome of mouse embryonic stem cells committed to the hematopoietic differentiation. Mouse embryonic stem cells sorted for Bry and Flk1 were generated from biological replicates. 100 μg of nuclear lysate were digested with trypsin to produce peptides that were labeled with 4-plex iTRAQ^TM^ reagent. Combined samples were then enriched for phosphopeptides via TiO~2~ column, separated with strong cation exchange chromatography (SCX) and subjected to nano-RPLC-MS/MS on a QTof mass spectrometer. **(C)** Distribution of the phosphoentity quantification ratios. Data normalization was obtained transforming all control ratios of phosphoentities identified with a sequence confidence above 20% with the logarithmic function at the base 2 (bins ranging from −2 to 2).](oncotarget-06-10924-g001){#F1}

Relative quantification of phosphorylation changes occurring in the hemangioblast formation {#s2_2}
-------------------------------------------------------------------------------------------

Significance thresholds and quantitative phosphorylation changes were determined according to previous analysis \[[@R4]--[@R15]--[@R16]\]. To establish whether there was a change in peptide phosphorylation, only phosphopeptides exceeding 95% of the identifications compared to the control:control ratio (Bry^−^Flk1^−^: Bry^−^Flk1^−^) were considered. The interval of significance was calculated for each replicate based on the normal distribution of the internal control ratio (Figure [1C](#F1){ref-type="fig"}). Phosphorylation level was considered significantly changing when the fold change was \< 0.6 (decrease) or \> 1.5 (increase). Phosphopeptides with a ratio within the intervals of significance were manually removed from the data. Spectra were then manually checked to verify phosphorylation assignment, based on intact fragment presence, neutral loss of HPO~3~ (80 Da) or neutral loss of H~3~PO~4~ (98 Da). Using these stringent selection criteria 37 phosphoentities were of interest as they change during ES cell differentiation (see Table [1](#T1){ref-type="table"}). With the exception of Vars, the phosphopeptides have been also identified in other phosphoproteomic analyses \[[@R17]--[@R20]\]. For only 9 phosphopeptides, the modification site and the protein kinase were determined using site-specific methods (referring to the phosphorylation site repository found on <http://www.phosphosite.org/>: 178226 non-curated sites, 103952 sites curated from literature) (Table [2](#T2){ref-type="table"}). Regarding those peptides included in Table [1](#T1){ref-type="table"}, epiblast cells shown 7 phosphoentities up-regulated and 14 phosphoentities down-regulated; early mesoderm cells exhibited 6 phosphoentities up-regulated and 12 phosphoentities down-regulated; in the hemangioblast 10 phosphoentities were up-regulated and 16 phosphoentities down-regulated.

###### Phosphopeptides identified as changing in differentiating ES on analysis of iTRAQ^TM^ relative quantification

  Acc.nb   Gene name   Protein name                                    Phosphopeptide sequence                 Bry^+^Flk-: Bry-Flk-   Bry^+^Flk^+^: Bry^+^Flk^−^   Bry^+^Flk^+^: Bry^−^Flk^−^   GO Biological Process                                                                                                                                      GO Molecular Function
  -------- ----------- ----------------------------------------------- --------------------------------------- ---------------------- ---------------------------- ---------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------
  P57776   Eef1d       eEF1d protein                                   GATPAEDDE DKDIDLFG **pS**DEEEEDKEAAR    **1.5**                [1.09]{.ul}                  **1.61**                     Positive regulation of NF-kB cascade                                                                                                                       Signal transducer activity; Translational elongation factor activity
  P57776   Eef1d       eEF1d protein                                   ATAPQTQ HV**pS**PMR                     **1.96**               [0.77]{.ul}                  [1.48]{.ul}                  Positive regulation of NF-kB cascade                                                                                                                       Signal transducer activity; Translational elongation factor activity
  Q6J1H4   Utf1        UTF1                                            RLPAFSPP SPA**pS**PDAELR                **0.36**               **0.5**                      **0.17**                     Transcription, DNA-dependent                                                                                                                               Transcription coactivator activity
  Q6J1H4   Utf1        UTF1                                            RLPAF**pS**PPS PA**pS**PDAELR           **0.38**               **0.42**                     **0.16**                     Transcription, DNA-dependent                                                                                                                               Transcription coactivator activity
  Q6J1H4   Utf1        UTF1                                            RLPAFSPP **pS**PASPDAELR                **0.37**               **0.54**                     **0.2**                      Transcription, DNA-dependent                                                                                                                               Transcription coactivator activity
  Q6J1H4   Utf1        UTF1                                            RLPAFSPP **pS**PA**pS**PDAELR           **0.31**               **0.58**                     **0.18**                     Transcription, DNA-dependent                                                                                                                               Transcription coactivator activity
  Q6J1H4   Utf1        UTF1                                            SAGDVPVTTS DAFATSGGM AEPG**pS**PK       **0.39**               **0.48**                     **0.19**                     Transcription, DNA-dependent                                                                                                                               Transcription coactivator activity
  P17095   Hmga1       High mobility group protein HMG-I/HMG-Y         KQPPV **pS**PGTALVGSQK                  [1.22]{.ul}            **0.59**                     [0.73]{.ul}                  Regulation of transcription; DNA-dependent, Negative regulation of cell proliferation                                                                      DNA-binding; Transcription coactivator activity
  P52927   Hmga2       High mobility group protein HMG-A2              KQQQEPTCEP **pS**PKRPR                  [1.29]{.ul}            **1.89**                     **2.38**                     Positive regulation of stem cell proliferation                                                                                                             A-T DNA binding
  Q9CQS8   Sec61b      Sec61 beta subunit                              PGPTPSGTNVGS **pS**GRSPSK               [1.07]{.ul}            **1.61**                     **1.71**                     Protein transport                                                                                                                                          Ribosome binding
  Q9CQS8   Sec61b      Sec61 beta subunit                              PGPTPSGTNV GSSGR**pS**PSK               [1.1]{.ul}             **1.52**                     **1.63**                     Protein transport                                                                                                                                          Ribosome binding
  P30999   Ctnnd1      Catenin delta-1 (p120 catenin)                  GSLA**pS**LDSLRK                        [0.78]{.ul}            [0.62]{.ul}                  **0.48**                     Wnt receptor signaling pathway; Regulation of transcription, DNA-dependent                                                                                 Protein phosphatase binding; Protein kinase binding
  Q8K019   Bclaf1      Bcl-2-associated transcription factor           IDI**pS**PSALRK                         **0.53**               [1.35]{.ul}                  [0.7]{.ul}                   Regulation of transcription, DNA-dependent; Positive regulation of apoptosis                                                                               Protein binding; DNA binding
  Q9WV60   Gsk3b       Glycogen synthase kinase 3b                     GEPNV**pS**YICSR                        **0.15**               [1.48]{.ul}                  **1.67**                     Genetic imprinting; Multicellular organismal development; Wnt receptor signaling pathway                                                                   Protein kinase binding; Transferase activity
  O88509   Dnmt3b      DNA (cytosine-5) methyltrans-ferase 3B          TTNDSAASE **pS**PPPKR                   **0.38**               **0.51**                     **0.19**                     Methylation: Epigenetic                                                                                                                                    Transferase activity
  Q01320   Top2a       Topoisomerase (DNA) II alpha                    KPIKYLEE **pS**DDDDDLF                  **0.52**               **1.58**                     0.81                         ATP catabolic process; Mitotic recombination; Embryonic cleavage                                                                                           DNA topoisomerase activity; Chromatin binding
  P14733   Lmnb1       Lamin B1                                        LKL**pS**PSPSSR                         [0.64]{.ul}            [0.77]{.ul}                  **0.48**                     G2/M-specific positive regulation of cyclin-dependent protein kinase activity Positive regulation of JNK cascade                                           JUN kinase binding; Phospholipase binding
  Q8BTI8   Srrm2       Serine/arginine repetitive matrix 2             MVQASSQSLLP PAQDRPR**p S**PVPSAFSDQSR   **0.59**               [0.78]{.ul}                  **0.46**                     RNA splicing; mRNA processing                                                                                                                              Protein N-terminus binding
  Q569Z6   Thrap3      Thyroid hormone receptor associated protein 3   RIDI**pS**PSTFR                         **0.56**               [1]{.ul}                     **0.55**                     Steroid hormone receptor signaling pathway; Transcription - DNA dependent                                                                                  Transcription coactivator activity; Nucleotide binding
  P97496   Smarcc1     SWI/SNF complex 155 kDa subunit                 RKP**pS**P **pS**PPPPTATESR             **1.6**                [0.75]{.ul}                  [1.2]{.ul}                   Chromatin remodeling; Organ morphogenesis; Transcription, DNA-dependent                                                                                    Protein binding; DNA binding
  Q8VDF2   Uhrf1       E3 ubiquitin-protein ligase UHRF1               RPLIA **pS**PSQPPPALR                   [0.82]{.ul}            [0.7]{.ul}                   **0.56**                     Cell proliferation; Regulation of transcription, DNA-dependent; Multicellular organismal development                                                       DNA binding; Methyl-CpG binding
  P60904   Dnajc5      DnaJ (Hsp40) homolog, subfamily C, member 5     SL**pS**TSGESL YHVLGLDK                 [1.35]{.ul}            [1.11]{.ul}                  **1.51**                     Protein folding; Negative regulation of neuron apoptosis                                                                                                   ATP-dependent protein binding; Heat shock protein binding; Unfolded protein binding
  Q8K310   Matr3       Matrin-3                                        TE**pS**PAE GKEQEEK                     **0.49**               [1.16]{.ul}                  **0.58**                     Unannotated                                                                                                                                                Nucleic acid binding
  Q9Z1Q9   Vars        Valyl-tRNA synthetase                           L**pS**ATVTEAF VRLHEEGVI                [1.44]{.ul}            **0.56**                     [0.79]{.ul}                  tRNA aminoacylation for protein translation                                                                                                                Aminoacyl-tRNA ligase activity; Nucleotide binding
  Q80XU3   Nucks1      Nuclear ubiquitous casein and cdk substrate     ATVTP **pS**PVKGK                       **0.56**               [0.85]{.ul}                  **0.47**                     Unannotated                                                                                                                                                DNA binding
  Q6PR54   Rif1        Rap1-interacting factor 1                       SSD**pS**VD IEEQEEK                     [0.69]{.ul}            **0.58**                     **0.37**                     Stem cell maintenance; cell cycle; Response to DNA damage stimulus                                                                                         Protein binding
  Q6PR54   Rif1        Rap1-interacting factor 1                       VSDSSL **pS**PEK                        [0.84]{.ul}            [0.64]{.ul}                  **0.53**                     Stem cell maintenance; cell cycle; Response to DNA damage stimulus                                                                                         Protein binding
  Q8CBW3   Abi1        Abl interactor 1                                TNPPTQKPP SPPV**pS**GR                  [0.99]{.ul}            **1.67**                     **1.64**                     Peptidyl-tyrosine phosphorylation; Cell motility                                                                                                           Protein binding; Protein tyrosine kinase activator activity
  Q08943   Ssrp1       FACT complex subunit SSRP1                      EGINPGYD DYAD**pS**DE DQHDAYLER         **1.56**               [0.68]{.ul}                  [1.05]{.ul}                  Regulation of transcription, DNA-dependent                                                                                                                 DNA binding
  Q64012   Raly        hnRNP-associated with lethal yellow             GRL**pS**PVPVPR                         **2.53**               **0.47**                     **1.37**                     RNA splicing; mRNA processing                                                                                                                              RNA binding
  Q9JIX8   Acin1       Acinus                                          HL**pS**HPEP EQQHVIQR                   [1.15]{.ul}            **0.52**                     **0.59**                     Apoptosis; Apoptotic chromosome condensation                                                                                                               Nucleic acid binding; Nucleotide binding
  P11499   Hsp 90ab1   Heat-shock protein hsp84                        IEDVG**pS**DE EDDSGKDK                  [0.55]{.ul}            [1.35]{.ul}                  [0.73]{.ul}                  Protein folding; Response to stress; Placenta development                                                                                                  Protein binding
  P42208   Sept2       Septin 2 (NEDD5 protein)                        IYHLPDAE **pS**DEDE DFKEQTR             [1.01]{.ul}            **1.68**                     **1.69**                     Cell cycle                                                                                                                                                 GTPase activity; Protein binding
  O54839   Eomes       Eomes                                           KG**pS**PC AEEELPS AATAAATAR            **1.52**               [0.76]{.ul}                  [1.15]{.ul}                  Blastocyst development; Multicellular organismal development; Stem cell maintenance; Mesoderm formation; Endoderm formation; Interferon-gamma production   DNA binding; Transcription factor activity
  Q9CW46   Raver1      Ribonucleoprotein PTB-binding 1                 LL**pS**PIASNR                          [1.33]{.ul}            **0.49**                     [0.65]{.ul}                  Unannotated                                                                                                                                                RNA binding
  Q6P4S8   Ints1       Integrator complex subunit 1                    LS**pS**TP PLSALGR                      **2.45**               [0.66]{.ul}                  **1.62**                     snRNA processing; Blastocyst growth; Inner cell mass cell proliferation; Apoptosis                                                                         Unannotated
  Q8CGU3   Pnn         Pinin                                           RGF**pS**D SGGGPPAK                     [1.26]{.ul}            [1.37]{.ul}                  **1.71**                     Cell-cell adhesion; Regulation of transcription, DNA-dependent; RNA splicing; mRNA processing                                                              DNA binding

To be considered as changing, a phosphopeptide should have a ratio outside the range in which 95% of phosphopeptides ratios for the internal control replicates are found. Phosphopeptides shown are those where a confident assessment of a significant decrease or increase was found. To be included the data must have a -fold change \<0.6 or \> 1.5 with a *p* value of less than 0.05. The significant changes are shown in bold; the underlined values represent changes where the confidence levels were not met. Every spectrum has been manually checked to verify phosphorylation. The first three columns report the Accession Number (UniProtKB-SwissProt), the Gene and Protein name, and the primary sequence of the phosphopeptide identified, indicating in bold the aminoacid modified by phosphorylation and in brackets the phosphosite position in the full length protein. The next three columns report the log(2) of the iTRAQ ratios representing the changes in phosphorylation level occurring during the progression of the hematopoietic differentiation, comparing Bry^+^Flk1^−^:Bry^−^Flk1^−^, Bry^+^Flk1^+^:Bry^+^Flk1^−^ and Bry^+^Flk1^+^:Bry^−^Flk1^−^. The last two columns show the Biological process and Molecular function classification for the reported phosphopeptide-derived proteins, according to the Gene Ontology annotations. Data from two independent biological replicate were merged into the table.

###### Phosphosite retrieved informations based on mass spectrometry identification and esperimental evidences

  Acc.nb   Gene name   Protein name                                    Phosphopeptide sequence                 (P)site position   MS evidence   EX evidence   Protein kinase
  -------- ----------- ----------------------------------------------- --------------------------------------- ------------------ ------------- ------------- ----------------
  P57776   Eef1d       eEF1d protein                                   GATPAEDDED KDIDLFG**pS**D EEEEDKEAAR    S162               Y             Y             CK2
  P57776   Eef1d       eEF1d protein                                   ATAPQTQ HV**pS**PMR                     S133               Y             Y             Cdc2
  Q6J1H4   Utf1        UTF1                                            RLPAFSPP SPA**pS**PDAELR                S18                Y             N             
  Q6J1H4   Utf1        UTF1                                            RLPAF**pS**P PSPA**pS**PDAELR           S12, S18           Y             N             
  Q6J1H4   Utf1        UTF1                                            RLPAFSPP **pS**PASPDAELR                S15                Y             N             
  Q6J1H4   Utf1        UTF1                                            RLPAFSPP **pS**PA**pS**PDAELR           S15, S18           Y             N             
  Q6J1H4   Utf1        UTF1                                            SAGDVPVT TSDAFATS GGMAEPG**pS**PK       S48                Y             N             
  P17095   Hmga1       High mobility group protein HMG-I/HMG-Y         KQPPV **pS**PGTALVGSQK                  S36                Y             Y             CDK2, HIPK2
  P52927   Hmga2       High mobility group protein HMG-A2              KQQQEPT CEP**pS**PKRPR                  S44                Y             Y             Cdc2
  Q9CQS8   Sec61b      Sec61 beta subunit                              PGPTPSGTN VGS**pS**GRSPSK               S14                Y             N             
  Q9CQS8   Sec61b      Sec61 beta subunit                              PGPTPSGTN VGSSGR**pS**PSK               S17                Y             N             
  P30999   Ctnnd1      Catenin delta-1 (p120 catenin)                  GSLA**pS**LDSLRK                        S346               Y             N             
  Q8K019   Bclaf1      Bcl-2-associated transcription factor           IDI**pS**PSALRK                         S656               Y             N             
  Q9WV60   Gsk3b       Glycogen synthase kinase 3b                     GEPNV**pS**YICSR                        S215               Y             N             
  O88509   Dnmt3b      DNA (cytosine-5) methyltransferase 3B           TTNDSAASE **pS**PPPKR                   S399               Y             N             
  Q01320   Top2a       Topoisomerase (DNA) II alpha                    KPIKYLEE **pS**DDDDDLF                  S1521              Y             Y             PLK1, CK2
  P14733   Lmnb1       Lamin B1                                        LKL**pS**PSPSSR                         S392               Y             N             
  Q8BTI8   Srrm2       Serine/arginine repetitive matrix 2             MVQASSQSLLP PAQDRPR**pS**P VPSAFSDQSR   S2404              Y             N             
  Q569Z6   Thrap3      Thyroid hormone receptor associated protein 3   RIDI**pS**PSTFR                         S679               Y             N             
  P97496   Smarcc1     SWI/SNF complex 155 kDa subunit                 RKP**pS**P**pS**P PPPTATESR             S327, S329         Y             N             
  Q8VDF2   Uhrf1       E3 ubiquitin-protein ligase UHRF1               RPLIA**pS**PS QPPPALR                   S289               Y             N             
  P60904   Dnajc5      DnaJ (Hsp40) homolog, subfamily C, member 5     SL**pS**TSGES LYHVLGLDK                 S10                Y             Y             AKT
  Q8K310   Matr3       Matrin-3                                        TE**pS**PAEGKEQEEK                      S619               Y             N             
  Q9Z1Q9   Vars        Valyl-tRNA synthetase                           L**pS**ATVTEA FVRLHEEGVI                N.R.               N             N             
  Q80XU3   Nucks1      Nuclear ubiquitous casein and cdk substrate     ATVTP**pS**PVKGK                        S181               Y             Y             CDK2
  Q6PR54   Rif1        Rap1-interacting factor 1                       SSD**pS**VDIEEQEEK                      S1565              Y             N             
  Q6PR54   Rif1        Rap1-interacting factor 1                       VSDSSL**pS**PEK                         S1683              Y             N             
  Q8CBW3   Abi1        Abl interactor 1                                TNPPTQKPP SPPV**pS**GR                  S187               Y             N             
  Q08943   Ssrp1       FACT complex subunit SSRP1                      EGINPGYDD YAD**pS**DED QHDAYLER         S444               Y             N             
  Q64012   Raly        hnRNP-associated with lethal yellow             GRL**pS**PVPVPR                         S135               Y             Y             CDK2
  Q9JIX8   Acin1       Acinus                                          HL**pS**HPEPEQQHVIQR                    S710               Y             N             
  P11499   Hsp90ab1    Heat-shock protein hsp84                        IEDVG **pS**DEEDDSGKDK                  S255               Y             Y             TK, CK2
  P42208   Sept2       Septin 2 (NEDD5 protein)                        IYHLPDAE **pS**DEDEDFKEQTR              S218               Y             Y             
  O54839   Eomes       Eomes                                           KG**pS**PCAEE ELPSAATAAATAR             S117               Y             N             
  Q9CW46   Raver1      Ribonucleoprotein PTB-binding 1                 LL**pS**PIASNR                          S576               Y             N             
  Q6P4S8   Ints1       Integrator complex subunit 1                    LS**pS**TPPLSALGR                       S82                Y             N             
  Q8CGU3   Pnn         Pinin                                           RGF**pS**DSGGGPPAK                      S66                Y             N             

The first three columns report the Accession Number (UniProtKB-SwissProt), the Gene and Protein name, and the primary sequence of the phosphopeptide identified, indicating in bold the aminoacid modified by phosphorylation and in brackets the phosphosite position in the full length protein. The next three columns report the phosphosite position with respect to the protein primary sequence, whether the site has been identified by mass-spectrometry based methods (MS evidence) and experimental methods (EX evidence). Y = yes, N = no. These informations were retrieved from PhosphositePlus; experimental methods include aminoacid sequencing, site-directed mutagenesis, modification site-specific antibodies and targeted MS strategies. The last column report the protein kinase responsible for the specific site phosphorylation, identified by EX evidences.

We focused the data analysis on early phosphorylative changes, occurring in the first stages of the differentiation process, proceeding from the epiblast to the early mesoderm cells (Bry^+^Flk1^−^ and Bry^−^Flk1^−^), and those which are differentially regulated in the BL-CFC cells (Bry^+^Flk1^+^). According to this analysis, phosphopeptides can be divided into 3 groups. Group 1: phosphopeptides up- or down-regulated during early mesoderm differentiation. Group 2: phosphopeptides up- or down-regulated in BL-CFC cells. Group 3: phosphopeptides changing neither in Bry^−^Flk1^−^, Bry^+^Flk1^−^ nor Bry^+^Flk1^+^. Interestingly, almost half of the phosphopeptides that were differentially regulated in the Bry^+^Flk1^−^ and Bry^−^Flk1^−^, were not changing in the Bry^+^Flk1^+^ and *vice versa*. Only phosphopeptides emanated from Ef1d and Ints1 were up-regulated either in the progression from Bry^−^Flk1^−^ to Bry^+^Flk1^−^ and in the Bry^+^Flk1^+^; Utf1, Dnmt3b, Srrm2 Thrap3, Matr3 and Nucks1 phosphopeptides were instead down-regulated in both stages. Only phosphopeptides belonging to the proteins Hmga1, Vars and Raver1 were neither changing in the progression Bry^−^Flk1^−^ to Bry^+^Flk1^−^ and in the hemangioblast cells, indicating that post-translational regulation involving these proteins may be fundamental for the transition from the Bry^+^Flk1^−^ to Bry^+^Flk1^+^.

The regulation of consequential temporal processes, by means of phosphorylation, governed the hemangioblast development {#s2_3}
-----------------------------------------------------------------------------------------------------------------------

Comparing the phosphopeptides changing in Bry^+^Flk1^+^ and those which occur in the very early steps of differentiation, according to the Gene Ontology, different categories of biological processes were involved (Figure [2](#F2){ref-type="fig"}). Proteins involved in regulation of cell differentiation and gene expression, developmental processes and especially embryonic development, such as Ints1, Top2a, Dnmt3b and Gsk3b, Utf1, Bclaf1, Thrap3 and Ssrp1, were found to be differentially phosphorylated in all the three stages of ES cells differentiation (Figure [2A](#F2){ref-type="fig"} and [2C](#F2){ref-type="fig"}). Phosphorylation on Ints1 and Dnmt3b was regulated the same in Bry^+^Flk1^−^:Bry^−^Flk1^−^ and Bry^+^Flk1^+^:Bry^−^Flk1^−^; Top2a decreased in Bry^+^Flk1^−^:Bry^−^Flk1^−^, but it didn\'t change in the Bry^+^Flk1^+^ while Gsk3b phosphorylation decreased as cells started to differentiate, then progressively increased as cells became Bry^+^Flk1^+^.

![Biological classification of differentially regulated phosphopeptides\
Pie chart representation of the phosphopeptide-emanated proteins classified into groups by Biological process. Phosphopeptides from Group 1 (up- or down-regulated in Bry^−^Flk1^−^ and Bry^+^Flk1^−^) and Group 2 (up- or down-regulated in Bry^+^Flk1^+^) were considered as they are indicative for the regulation of stem cell differentiation. The relative frequency of over-represented categories is reported as percentage in the pie charts. **(A)** and **(C)** Biological processes of phosphopeptides differentially regulated both in Group 1 and Group 2, respectively. **(B)** and **(D)** Biological processes specific to phosphopeptides differentially regulated either in Group 1 or Group 2. Gene Ontology classification was performed using the plugin BiNGO v2.42 within Cytoscape v.2.8.2, assessing over-represented categories with a hypergeometric statistical test and Benjamini & Hochberg False Discovery Rate correction (*p* \< 0.05). As a reference set, the whole mouse repository annotation was used.](oncotarget-06-10924-g002){#F2}

However, as expected, there are processing taking place in a consequential temporal pattern. As mES cells started to differentiate, phosphopeptides significantly changing were emanated from proteins involved in blastocyst and placenta development, the formation of the primary germ layer and mesoderm; such as Eomes, Hsp90ab1, Smarcc1 and Gsk3b. Conversely, as the BL-CFC cells were formed, differentially phosphorylated peptides emanated from proteins involved in cell cycle, cell division and mRNA processing such as Uhrf1, Sept2, Rif1, Hmga2, Srrm2 and Pnn; in the regulation of phosphorylation and kinase activity, such as the Wnt receptor signaling pathway (Ctnnd1 and Abi1) and the JAK-STAT cascade (Hmga2). Notably, few proteins also had a role in cell-cell adhesion and cell motility, such as Ctnnd1, Pnn and Rif1.

Comparison with expression dataset {#s2_4}
----------------------------------

Twenty-one phosphopeptides within this dataset were found to emanate from proteins analyzed in the nuclear proteome expression analysis associated with Bry and Flk1 expression previously published \[[@R4]\] (Figure [3](#F3){ref-type="fig"}). Although the expression of the proteins did not change during hematopoietic differentiation, 9 phosphopeptides displayed differential regulation: Hmga1, Sec61b, Ctnnd1, Gsk3b, Dnajc5, Nucks1, Rif1, Ssrp1, Raver1. Among these, phosphorylation on Hmga1 and Raver1 only decreased in the progression from Bry^+^Flk1^−^ to Bry^+^Flk1^+^; while Raver1 is involved in the regulation of alternative splicing \[[@R21]\], Hmga1 plays a role in modulation of gene expression during development and embryogenesis, and its expression is known to be markedly diminished in differentiated cells \[[@R22]\]. Interestingly, Ctnnd1, Gsk3 and Rif1, are involved either in the regulation of cell differentiation and developmental processes, but also in the regulation of the cellular response to signaling pathways, such as the Wnt receptor signaling pathway. Moreover, GSK3 was found to play a pivotal role in controlling the decision fate of ES cells between self-renewal and differentiation; in fact inhibition of GSK3 has been found to promote and maintain mESC self-renewal \[[@R23]\]. As shown in Figure [3](#F3){ref-type="fig"}, in the majority of the cases normalization against protein level revealed no protein level change modulating stoichiometry of phosphorylation. For example, Hmga2 expression was augmented as ES cells differentiate and it remains high in the Bry^+^Flk1^+^: we found a peptide whose phosphorylation increased as mES cells differentiate, and this phosphorylation is maintained in the Bry^+^Flk1^+^ population. Hmga2 can exert a negative regulation on the Jak-Stat signaling cascade \[[@R24]\]. The Jak/Stat pathway promotes ESCs self-renewal \[[@R25]\] and is required for self-renewal of *Drosophila* sperm stem cells \[[@R26]\]. Conversely, only few phosphopeptides did not exhibit a correspondence between phosphorylation and protein expression. Among these, is the phosphopeptide emanating from the chromatin remodeling factor Smarcc1/Baf155, whose phosphorylation increased as mESCs differentiated toward mesoderm lineage commitment. Interestingly, Schaniel et co-workers \[[@R27]\], showed that Smarcc1 plays a balance between gene repression, which maintains ESCs in the self-renewal state and chromatin rearrangements, that led to the expression of genes involved in differentiation.

![Comparison between phosphopeptides and protein expression levels\
Panels show changes in identified phosphopeptides compared to the expression profile of the referring proteins previously identified \[[@R4]\]. *Blue histograms* represent phosphorylation and *orange histograms* refer to protein expression level changes in Bry^−^Flk1^−^ (Epiblast-like cells), Bry^+^Flk1^−^ (Early mesoderm) and Bry^+^Flk1^+^ (Hemangioblast).](oncotarget-06-10924-g003){#F3}

DISCUSSION {#s3}
==========

Phosphoproteomic data can be a powerful tool to broaden understand of ES cells and how their ultimate fate is determined. Many transcription regulators such as epigenetic and transcription factors, as well as a large number of kinases are phosphorylated in embryonic stem cells \[[@R18]--[@R28], [@R29]\], suggesting that these post-translational modifications play a key role in determining stem cell fate. Our study reported the identification of novel phosphosites within proteins involved in ES cell mesoderm differentiation and the relative quantification of the phosphorylation stoichiometry during the progression from epiblast-like cells to the hemangioblast (BL-CFC cells).

The Gene Ontology classification highlighted that different biological processes play a role during the mesoderm-induced mESCs differentiation. During differentiation, phosphopeptides emanated from proteins involved in embryonic development were identified. In the last stage, when the hemangioblast is formed, phosphorylation differentially influences proteins involved in cell cycle, regulation of transcription and signaling pathways, indicating that mass spectrometry and phosphoproteomic analysis identified key modulators of the development process toward blood. For example, we reported a phosphopeptide emanated from Uhrf1 (also called Np95), which is known to contain a cyclin A/E-Cdk2 phosphorylation site. It has been demonstrated not only that Uhrf1 is essential for maintaining genomic methylation in embryonic stem cells by recruiting DNA methyltransferase (Dnmt) 1 to hemi-methylated CpG sites generated during replication \[[@R30]\], but also to interact with *de novo* methyltransferases Dnmt3a and Dnmt3b, mediating promoter silencing before DNA methylation is detected \[[@R31]\]. Uhtf1 is also involved in the regulation of Top2a. It has been suggested that Uhrf1 regulates transcription of Top2a by binding to an inverted 5′-CCAAT-3′ box in the Top2a promoter and activating expression \[[@R32]\]. Moreover it has been established that Uhfr1 contributes to genomic stability functioning in the response pathways against DNA damage and replication arrest \[[@R33]\]. Phosphopeptides emanated from both Top2a and Dnmt3b were found within our dataset.

Of particular interest was the identification of a phosphopeptide emanated from GSK3b, which phosphorylation increases as stem cells differentiate. GSK3b activity has been demonstrated to be crucial for the switch between stem cell self-renewal and differentiation. The regulation of GSK3 activity is able to inhibit self-renewal and promote differentiation \[[@R34]\]. But GSK3 functions in a wide range of cellular processes and it can both act as a tumor suppressor and as oncogene, in the development of various human cancers \[[@R35]--[@R37]\]. Of the phosphopetide emanated proteins within our dataset, 7 proteins present with at least 1 potential site that can be phosphorylated by GSK3b with high stringency (<http://scansite3.mit.edu>) (Acin1, Blacf1, Dnmt3b, Pnn, Rif1, Srrm2, Thrap3). Only 1 of the phosphopeptides identified contain the putative GSK3b consensus sequence (Abi1, medium stringency).

Another interesting protein was the Smarcc1/Baf155, that we found to be phosphorylated on S327 and S329; the phosphorylation of this doubly phosphorylated peptide decreased as stem cells differentiate toward the mesoderm commitment. Smarcc1/Baf155 belongs to the SWI/SNF multiprotein chromatin remodeling complex, and is required for heterochromatin formation and chromatin condensation during differentiation. In human ES cells, Smarcc1/Baf155 plays a dual role in maintaining pluripotency: it can promote or repress self-renewal gene expression, e.g. Nanog \[[@R38]\]. Furthermore, the SWI/SNF chromatin-remodeling complex also promotes somatic cell reprogramming by facilitating Oct4 binding to its target promoters. In retinoic acid-mediated differentiation, Baf155 can integrate p53 function to regulate ectodermal and mesodermal gene expression \[[@R27]\]. The possibility of Aurka-mediated p53 phosphorylation altering the interaction between p53 and the SWI/SNF complex as well as other epigenetic regulatory complexes is particularly tantalizing and may, in part, explain the apparent paradoxical requirement for SWI/SNF in both ESC maintenance and differentiation. As *in silico* analysis suggests (<http://scansite3.mit.edu>), Erk1 might be the kinase deputated to phosphorylate S327 and S329. Recently, Erk1/2, as GSK3b, was found to promote self-renewal, maintaining cellular growth capacity and reinforcing suppression of commitment \[[@R39]--[@R40]\].

We are only beginning to understand the molecular and cellular mechanisms of normal hematopoietic development and many pieces of these puzzle are still missing. The *in vitro* differentiation of ES cells has been instrumental in the identification and characterization of the hemangioblast.

Understanding how blood cells are generated is important from a biological perspective but also has potential implications in the treatment of blood diseases. Searches for post-translational regulatory processes are likely to lead to the identification of new important players in blood specification than can be altered in blood cancers. Knowing how signaling molecules regulates, by phosphorylation, their downstream targets could represent a precise stem cell signaling process that can lead to blood cancers, if unregulated or disrupted.

MATERIAL AND METHOD {#s4}
===================

Cell culture and differentiation {#s4_1}
--------------------------------

The Bry^+^ ES cell line was generated by Fehling et al. \[[@R3]\], introducing the GFP gene into one allele of the Bry (Brachyury) gene of the mouse embryonic stem cell line clone E14.1. ES cells were maintained and differentiated as previously described \[[@R3]\].

Cell sorting flow cytometry {#s4_2}
---------------------------

EBs were harvested, trypsinized and the single cell suspension analyzed on a FacsCalibur flow cytometer (BD Bioscences). Staining and isolation of cell populations were performed as previously described \[[@R3]\]. The expression of Bry with the Flk1 receptor in a temporal pattern revealed the emergence of three distinct populations, Bry^−^Flk1^−^, Bry^+^Flk1^−^, Bry^+^Flk1^+^, which represented a developmental progression from epiblast-like to early mesoderm then BL-CFC cells \[[@R3]\]. These sorted populations were used for analysis of the phosphoproteome.

Nuclear isolation {#s4_3}
-----------------

Nuclear extraction was performed using the Nuclear Extract kit (Active Motif, Brussels, Belgium) as previously described \[[@R41]\]. Briefly, 1×10^7^ cells from each sorted population were washed in ice cold Hanks buffer (136.7 mM NaCl, 5.35 mM KCl, 0.812 mM MgSO~4~, 1.28 mM CaCl~2~, 5.5 mM Glucose, 24 mM Hepes, pH 7.4) with phosphatase inhibitors and then lysed in hypotonic buffer, following the manufacturer\'s instructions. Nuclei were then lysed in 1 M triethylammonium bicarbonate lysis buffer (TEAB, Sigma-Aldrich, St. Louis, MO), 0.05% (w/v) SDS, protease inhibitor cocktail, phosphatase inhibitors and Benzonase (Novagen, UK). The protein concentration was determined using the Bradford protein assay (Bio-Rad, Hemel Hempstead, UK). The nuclear purity was assessed by Western Blot analysis for nuclear (lamin a/c) and cytoplasmic (β-tubulin) markers.

4-plex iTRAQ^TM^ labeling {#s4_4}
-------------------------

An aliquot of 100 μg of each nuclear protein sample was reduced, digested and labeled with four-channel iTRAQ^TM^ reagent (Applied Biosystem, Framingham, MA) according with the manufacturer\'s instructions. As previously described \[[@R41]\], protein were reduced with 50 mM tris-(2-carboxyethyl)phosphine, then alkylated by adding 200 mM methylmethanethiosulphate. Trypsin (5 μg, 0.5 μg/μl, Promega) was added, and the samples were incubated overnight at 37°C. After cooling to room temperature, peptides were dried, reconstituted in 20 μl TEAB and labeled with iTRAQ^TM^ reagent. In all experiments isobaric labeling exceeded 99% of total identified peptide using mass spectrometry. The four isobarically labeled reactions were pooled together and dried down.

TiO~2~ phospho-enrichment {#s4_5}
-------------------------

The iTRAQ^TM^ labeled peptide mixture was resuspended in 150 μl of lactate loading buffer (240 mg/ml lactate in 80% (v/v) Acetonitrile, 1% (v/v) Trifluoro-acetic acid (TFA). TiO~2~ columns (TopTip, Glygen, Corp, USA) were equilibrated with 150 μl of lactate loading buffer then the samples loaded. The tip was washed twice with 60 μl of lactate loading buffer and four times with 60 μl of wash buffer (80% (v/v) Acetonitrile, 5% (v/v) TFA). Bound peptides were then recovered by elution in 60 μl of elution buffer (ammonium water \[20 μl NH~3~ in 980 μl H~2~O\], pH 10.5). samples were then concentrated to a few μl in a SpeedVac prior to Strong Cation Exchange (SCX) chromatography.

SCX fractionation {#s4_6}
-----------------

Enriched phosphopeptides were fractionated off-line using an SCX cation exchange column (10 cm × 2.1 mm PolyLCPolysulfoethyl A column, 5 μm beads, 200 μÅ pore size (The Nest Group, Southborough, MA, USA) on a LC Packings Ultimate LC system running at 250 μl/min. Peptides were diluted 10-fold in SCX loading buffer (10 mM KH~2~PO~4~ in 25% (v/v) ACN, pH 2.7). The eluate was collected in 1 min intervals over the following gradient of increasing salt concentration: a 45 min linear gradient of 0--250 mM KCl, followed by a 10 min linear gradient of 250--500 mM KCl, then 5 min of 1 M KCl. Each fraction was then lyophilized in a SpeedVac concentrator (Labconco).

Mass spectrometry {#s4_7}
-----------------

Peptides were analyzed using a QStar^®^ XL mass spectrometer (AB Sciex, Warrington, UK) as previously described \[[@R41]\]. Briefly, dried peptide fractions were resuspended in 120 μl of Buffer A (2% (v/v) acetonitrile 0.1% (v/v) formic acid). For each analysis 60 μl of sample was loaded onto a on-line column (15 length;75 μm inner diameter) packed with RP C~18~ PepMap100 (3 μm, 100 A) using a Ultimate pump (LC Packings, Amsterdam, Netherlands) and separated over a 120 min solvent gradient from 5.9% (v/v) acetonitrile/0.1% (v/v) formic acid to 41% (v/v) acetonitrile/0.1% (v/v) formic acid coupled to a QStar^®^ XL mass spectrometer (AB Sciex, Warrington, UK). Data were acquired using an information dependent acquisition (IDA) designed with Analyst QS 2.0 (AB Sciex, Warrington, UK) where, for each cycle, the two most abundant multiply charged peptides (2+ to 4+) above a 20 count threshold in the MS scan with m/z between 400 and 2000 were selected for MS/MS. Each ion was selected a maximum of two times, and then dynamically excluded (± 50 mmu) for 40 seconds.

Data analysis {#s4_8}
-------------

Spectra were processed using ProteinPilot^TM^ v.3 software (Paragon algorithm v.3.0.0.0, AB Sciex, Warrington, UK), searching against a mouse Celera Discovery System database (mouse_KBMS5_0\_20050302, 115.660 entries). Default search parameters were set with MS tolerance of 0.5 Da, MS/MS tolerance of 0.1 Da. Identification focus was on biological modifications with phosphorylation emphasis as a special factor. Search parameters include methylmethanethiosulfonate (MMTS) alkylation of cysteine, iTRAQ^TM^ modification of lysine and N-terminal residues. The searched parameter was set for reverse searching for false discovery, so that at the 95% confidence level there is a false positive identification rate of \< 1%. Ratio values for each phosphoentity were obtained from weighted averages of multiple spectra when appropriate, similarly to the way ProteinPilot^TM^ calculates ratios for proteins. Phosphopeptides identified with a confidence ≥ 20 were included in the analysis. ProteinPilot^TM^ biases were used to correct for any sampling error so that the median value of log2(ratios) of the phosphoentity distribution is equal to 0 for each pair of iTRAQ^TM^ reagents. The distribution of the biological replicates Control(Bry^−^Flk^−^):Control(Bry^−^Flk^−^) was used to determine the biological variability of the procedure by combining the 2 control ratios. Student\'s *t* test was performed between the values of 2 biological replicates for each appropriate ratio and the Gaussian distribution of the biological replicates. Phosphoentities with a Student\'s *t*-test *p* value \< 0.05 were considered as potentially changing. Phosphoentities changing between the controls, i.e. for Bry^−^Flk^−^:Bry^−^Flk^−^ ratio, with a *p* value \< 0.05 were manually removed from the analysis. All the phosphorylation events were validated manually using the spectral data acquired. The phospho-dataset was then compared with the dataset obtained from the total nuclear expression analysis \[[@R4]\].
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